SCHEMBL16612609

SCHEMBL16612609

COc1ccc(C=CC2=CC(=O)[C@H]3C[C@@H]2C3(C)C)c(O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP1B1 Q16678 2/20 0.47
TYR P14679 2/20 0.45
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
GSK3B P49841 1/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
AR P10275 1/20 0.39
MAPT P10636 2/20 0.38
APP P05067 1/20 0.38
BACE1 P56817 1/20 0.38
MAOB P27338 1/20 0.36
NPC1 O15118 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
ERN1 O75460 1/20 0.36
CHRNA7 P36544 1/20 0.35
ALOX5 P09917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612717 1.00 CYP1A1 (0.47) CYP1A1CYP1A2CYP1B1TYRTRIM24
SCHEMBL30284575 1.00 CYP1A1 (0.47) CYP1A1CYP1A2CYP1B1TYRTRIM24
SCHEMBL16612610 1.00 CYP1A1 (0.47) CYP1A1CYP1A2CYP1B1TYRTRIM24
SCHEMBL16612832 0.85 CYP1A1 (0.48) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL16612833 0.85 CYP1A1 (0.48) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL16612834 0.85 CYP1A1 (0.48) CYP1A1CYP1A2CYP1B1MEN1KMT2A
SCHEMBL23931215 0.84 APP (0.45) CYP1A1CYP1B1MAPTAPPBACE1
SCHEMBL16612399 0.84 APP (0.45) CYP1A1CYP1B1MAPTAPPBACE1
SCHEMBL23931216 0.84 APP (0.45) CYP1A1CYP1B1MAPTAPPBACE1
SCHEMBL16612400 0.84 APP (0.45) CYP1A1CYP1B1MAPTAPPBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US claimed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP claimed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US claimed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP claimed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US claimed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US claimed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US claimed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP claimed
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2024-12-19 US disclosed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP disclosed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US disclosed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP disclosed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US disclosed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US disclosed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US disclosed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP1A1 2645/4885CYP1A2 2981/4885CYP1B1 3211/4885
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease CASP3, DCX, BAX CYP1A1 2645/4885CYP1A2 2981/4885CYP1B1 3211/4885
US-20240415787-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES SMAD3, TGFB1, TGFB2 CYP1A1 1491/4885CYP1A2 1795/4885CYP1B1 2045/4885
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX CYP1A1 2645/4885CYP1A2 2981/4885CYP1B1 3211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.